[ad_1]
(CercleFinance.com) – Acticor Biotech announces that the Paris Commercial Court has ordered the opening of a receivership procedure in its favor, thereby extending the biopharmaceutical company’s cash horizon to January 2025.
As soon as the receivership procedure is opened, a six-month observation period is planned, renewable. The objective is to allow Acticor to evaluate all the solutions allowing it to continue its development.
Acticor has asked Euronext to suspend its stock market price from August 7 until further notice given the uncertainty regarding the outcome of the procedure and the steps taken by the company.
[ad_2]
Source link -86